采纳股份收盘上涨3.38%，滚动市盈率80.61倍，总市值28.80亿元

Group 1 - The core viewpoint of the news is that Canan Co., Ltd. has seen a significant decline in its financial performance, with a notable drop in revenue and net profit in the latest quarterly report [1] - As of August 1, Canan's stock closed at 23.56 yuan, up 3.38%, with a rolling PE ratio of 80.61, marking a new low in 91 days, and a total market capitalization of 2.88 billion yuan [1] - The average PE ratio for the medical device industry is 53.65, with a median of 37.22, placing Canan at the 100th position in the industry ranking [1] Group 2 - Canan Co., Ltd. specializes in the research, production, and sales of injection and puncture devices and laboratory consumables, recognized as a specialized and innovative small and medium-sized enterprise in Jiangsu Province [1] - The latest quarterly report for Q1 2025 shows that Canan achieved an operating revenue of 72.71 million yuan, a year-on-year decrease of 34.28%, and a net profit of 7.68 million yuan, down 69.34%, with a gross profit margin of 31.15% [1] - As of July 18, 2025, Canan had 7,532 shareholders, a decrease of 64 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]